• Other

    Other
  • CN

    CN
  • EU

    EU
  • USA

    USA
    • My cart
    In the shopping cart is not goods, to choose and buy!
    • Product Name
    • Size
    • Quantity
    • Amount
      Selected items : 0 pieces Total : CHECK OUT()
      EPOXOMICIN (BU 4061T)
      EPOXOMICIN (BU 4061T)

      Price：
      Market Price：

      This product is for research use only, not for human use. We do not sell to patients.
      Number： - + Pieces（InventoryPieces）
      InvivoChem Cat #: V0689
      CAS #: 134381-21-8Purity ≥98%

      Description: Epoxomicin (formerly also known as BU-4061T) is a novel, potent, selective, cell-permeable and irreversible proteasome inhibitor with anti-inflammatory activity, it inhibits primarily the CH-L activity of the 20S proteasome, while T-L and PGPH catalytic activities are also inhibited at 100- and 1000-fold reduced rate. The novel α-epoxy ketone moiety of Epoxomicin forms covalent bonds with residues in particular catalytic subunits of the enzyme, disabling activity.

      References: Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10403-8.

      Customer Validation
      Official Supplier of
      • VE
      • OF
      • YALE
      • hhmi
      • 香港大学

      详情页公告Product Catalog 2022

      Bulletin Board

      详情页公告Guide to Product Handling


      Publications Citing InvivoChem Products
      • Physicochemical and Storage Information
      • Protocol
      • Quality Control Documentation
      • Related Biological Data
      • Customer Review
      Molecular Weight (MW)554.72
      FormulaC28H50N4O7
      CAS No.134381-21-8
      Storage-20℃ for 3 years in powder form
      -80℃ for 2 years in solvent
      Solubility (In vitro)DMSO: 100 mg/mL (180.3 mM)
      Water: <1 mg/mL
      Ethanol: 100 mg/mL (180.3 mM)
      Other infoChemical Name: (2S,3S)-2-[[(2S,3S)-2-[Acetyl(methyl)amino]-3-methylpentanoyl]amino]-N-[(2S,3R)-3-hydroxy-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxobutan-2-yl]-3-methylpentanamide
      InChi Key: DOGIDQKFVLKMLQ-JTHVHQAWSA-N
      InChi Code: InChI=1S/C28H50N4O7/c1-11-16(5)21(30-27(38)23(17(6)12-2)32(10)19(8)34)25(36)31-22(18(7)33)26(37)29-20(13-15(3)4)24(35)28(9)14-39-28/h15-18,20-23,33H,11-14H2,1-10H3,(H,29,37)(H,30,38)(H,31,36)/t16-,17-,18+,20-,21-,22-,23-,28+/m0/s1
      SMILES Code: CC[[email protected]](C)[[email protected]](NC([[email protected]@H](N(C(C)=O)C)[[email protected]@H](C)CC)=O)C(N[[email protected]@H]([[email protected]](O)C)C(N[[email protected]@H](CC(C)C)C([[email protected]]1(C)OC1)=O)=O)=O
      SynonymsBU-4061T; BU 4061T; BU4061T; EPOXOMICIN;


      • Molarity Calculator
      • Dilution Calculator
      • The molarity calculator equation

        Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

        • Mass
        • Concentration
        • Volume
        • Molecular Weight *
        • =
        • ×
        • ×
      • The dilution calculator equation

        Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

        This equation is commonly abbreviated as: C1V1 = C2V2

        • Concentration (start)
        • ×
        • Volume (start)
        • =
        • Concentration (final)
        • ×
        • Volume (final)
        • ×
        • =
        • ×
        • C1
        •  
        • V1
        •  
        • C2
        •  
        • V2
      In Vitro

      In vitro activity: Epoxomicin covalently binds to the LMP7, X, MECL1, and Z catalytic subunits of the proteasome. Epoxomicin (100 nM) results in a 30-fold increase in the levels of p53 protein, a known target of the proteasome, in HUVECs. Epoxomicin (10 μM) results in the accumulation of ubiquitinated proteins in HeLa cells. Epoxomicin (10 μM) inhibits IκBα degradation by 10-fold in HeLa cells. Epoxomicin (10 μM) produces a significant dose-dependent reduction in TNF-α-stimulated NF-κB DNA-binding activity in HeLa cells. Epoxomicin inhibits proliferating of EL4 lymphoma cells with biotinylated chimerae with IC50 of 4 nM. Epoxomicin (1 μM) leads to a reduction of LCMV GP33 presentation and an enhancement of GP276 presentation.

      In VivoEpoxomicin (0.58 mg/kg per day) reduces the CS response by 44% relative to the control group of mice treated with vehicle alone. Epoxomicin (2.9 mg/kg) potently inhibits the irritant-associated inflammatory response by 95% when ear edema measurements are made 24 hours postchallenge in mice.
      Animal modelBALB/c mice
      Formulation & DosageDissolved in 10% DMSO/PBS; 2.9 mg/kg; i.p. injection
      ReferencesProc Natl Acad Sci U S A. 1999 Aug 31;96(18):10403-8.

      These protocols are for reference only. InvivoChem does not independently validate these methods.

      EPOXOMICIN

      Accumulation of p53 (A) and ubiquitinated proteins (B) in epoxomicin-treated cells. Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10403-8.
             		 

      EPOXOMICIN

      Epoxomicin inhibits activation of NF-κB. Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10403-8.
      		 

      EPOXOMICIN

      Epoxomicin inhibits inflammation in vivo. Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10403-8.

      EPOXOMICIN

      EPOXOMICIN

      EPOXOMICIN

      评论

        Home Prev Next Last page / pices

        发评论

        ×
        Your information is safe with us. * Required Fields.
        Products are for research use only;  We do not sell to patients
        Contact Us
        Contact Us
        Tel: 1-708-310-1919
        Fax: 1-708-557-7486
        Email: [email protected]
        Frequently Asked Questions
        Subscribe to our E-newsletter
        • Name*
        • *
        • E-mail*
        • *
        • instructions：
        • *
        Copyright 2020 InvivoChem LLC | All Rights Reserved
          Site map
        prompt
        Do you confirm the receipt?